Here, we report the preliminary safety and efficacy results of the combination of PD-1 blockade with a VEGFR small-molecule inhibitor in patients with chemotherapy-naïve mucosal melanoma, which demonstrate a manageable safety profile and durable antitumor activity. Here, KDR is linked to mucosal melanoma.